Hyun Cheol Chung
ORCID: 0000-0002-0920-9471Also affiliated with Yonsei University Health System
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study”.
Laura Q M Chow, Justin F Gainor, Patricia LoRusso, Keun-Wook Lee, Hyun Cheol Chung +14 more
Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges +21 more
Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen +12 more
Minori Rosales, Hyun Cheol Chung, Harry H Yoon, Lin Shen, Markus Moehler +2 more
Yanping Yang, Jaclyn E. McCloskey, Marjan Zaman, Yogindra Vedvyas, Xianglan Zhang +11 more